Linvas Tablet contains Saroglitazar 4 mg, a dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist indicated for the management of dyslipidemia and diabetic dyslipidemia. Saroglitazar effectively improves lipid and glucose metabolism by modulating PPAR pathways, resulting in decreased triglycerides, low-density lipoprotein cholesterol (LDL-C), and improved insulin sensitivity. Linvas is primarily prescribed for patients with type 2 diabetes mellitus who exhibit elevated triglyceride levels despite standard therapy. The tablet aids in reducing cardiovascular risk factors by addressing both hyperglycemia and dyslipidemia concurrently. Clinical studies have demonstrated its efficacy in lowering fasting plasma glucose, HbA1c, and serum lipid parameters, including total cholesterol and very low-density lipoprotein (VLDL). Linvas is generally well tolerated; however, monitoring liver enzymes and renal function during therapy is recommended due to potential adverse effects. It should be used as an adjunct to diet and exercise to achieve optimal metabolic control. Contraindications include hypersensitivity to Saroglitazar or any excipients, and caution is advised in patients with hepatic or renal impairment. Linvas Tablet offers a novel therapeutic option for comprehensive management of metabolic abnormalities associated with type 2 diabetes and dyslipidemia, contributing to improved patient outcomes.